Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Otsuka and Acucela enter dry AMD development agreement

Otsuka and Acucela enter dry AMD development agreement

8th September 2008

Otsuka Pharmaceutical and Acucela have signed a definitive agreement to co-develop ACU-4429, a compound currently in phase I of clinical development as a treatment for dry age-related macular degeneration (AMD).

Under the terms of the deal, both companies will develop the compound in this indication and for other conditions in North America.

Otsuka will pay an initial cash sum of $5 million (2.8 million pounds)

When the product is commercialised, both companies may co-promote the drug and will share all profits and expenses relating to sales for the compound in this region.

Otsuka will own the exclusive development and marketing rights for the drug in in Asia and selected worldwide markets while Acucela will retain the rights to ACU-4429, its lead compound, in Europe.

Taro Iwamoto, president and representative director of Otsuka Pharmaceutical, said: “Dry AMD causes progressive deterioration of visual function including narrowed vision and in many cases loss of eyesight, leading to severe impairment of one’s quality of life.”

He added his hopes that the joint efforts from both companies will result in the development of ACU-4429 as an effective treatment for patients with dry AMD.

Last week, Otsuka and Acucela signed a co-development agreement for Rebamipide Opthalmic Suspension as a treatment for dry eye.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.